Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × SCIO-469 × Plasma cell × Clear all
NCT00095680 2010-10-22

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

NCT00087867 2010-10-18

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
62 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡